Lipid metabolism, physical activity, and postmenopausal hormone therapy

American Journal of Kidney Diseases

Volumn 32, Issue 5 SUPPL. 3, 1998, Pages

  Wenger, Nanette K ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Coronary risk; Coronary risk reduction; General population; Lipid metabolism; Physical activity; Postmenopausal hormone therapy

Indexed keywords

ANTILIPEMIC AGENT;

CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CORONARY ARTERY DISEASE; CORONARY RISK; EXERCISE; FAT INTAKE; HORMONAL THERAPY; HUMAN; LIFESTYLE; LIPID METABOLISM; PHYSICAL ACTIVITY; PRACTICE GUIDELINE; REVIEW; TREATMENT INDICATION;

EID: 0031792619     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/ajkd.1998.v32.pm9820467     Document Type: Article

References (28)

1. Fuster V, Pearson TA: 27th Bethesda Conference: Matching the intensity of risk factor management with the hazard for coronary disease events. J Am Coll Cardiol 27:957-1047, 1995
2. Ramsay LE, Haq IU, Jackson PR, Yeo WW, Pickin DM, Payne JN: Targeting lipid-lowering drug therapy for primary prevention of coronary disease: An updated Sheffield table. Lancet 348:387-388, 1996
3. Expert Panel: Summary of the second report of the National Cholesterol Education Program (NECP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (ATP-II). JAMA 269: 3015-3023, 1993
4. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW, McKillop JH, Packard CJ, for the West of Scotland Coronary Prevention Study Group: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 333:1301-1307, 1995
5. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM Jr: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/Tex CAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279:1615-1622, 1998
6. Scandinavian Simvastatin Survival Study Group: Randomized trial of cholesterol lowering in 4,444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 344:1383-1389, 1994
7. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JMO, Wun C-C, Davis BR, Braunwald, for the Cholesterol and Recurrent Events Trial Investigators: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 335:1001-1009, 1996
8. US Department of Health and Human Services: Physical Activity and Health: A Report of the Surgeon General. Atlanta, GA, US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, 1996
9. NIH Consensus Development Panel on Physical Activity and Cardiovascular Health: Physical activity and cardiovascular health. JAMA 276:241-246, 1996
10. Fletcher GF, Balady G, Blair SN, Blumenthal J, Caspersen C, Chaitman B, Epstein S, Froelicher ES, Froelicher VF, Pina IL, Pollock ML: Statement on exercise: Benefits and recommendations for physical activity programs for all Americans. Circulation 94:857-862, 1996
11. Wenger NK: 40 years of progress: Physical activity in the primary and secondary prevention of heart disease, in American College of Sports Medicine 40th Anniversary Lectures. Indianapolis, IN, American College of Sports Medicine, 1994, pp 43-54
12. Wenger NK, Froelicher ES, Smith LK, Ades PA, Blumenthal JA, Certo CME, Dattilo AM, Davis D, DeBusk RF, Drozda JP Jr, Fletcher BJ, Franklin BA, Gaston H, Greenland P, McBride PE, McGregor CGA, Oldridge NB, Piscatella JC, Rogers FJ: Cardiac Rehabilitation. Clinical Practice Guideline No. 17. Rockville, MD, US Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research and the National Heart, Lung, and Blood Institute, 1995 (AHCPR Publication No. 96-0672)
13. Oldridge NB, Guyatt GH, Fischer ME, Rimm AA: Cardiac rehabilitation after myocardial infarction: Combined experience of randomized clinical trials. JAMA 260: 945-950, 1988
14. O'Connor GT, Buring JE, Yusuf S, Goldhaber SZ, Olmstead EM, Paffenbarger RS Jr, Hennekens CH: An overview of randomized trials of rehabilitation with exercise after myocardial infarction. Circulation 80:234-244, 1989
15. Fiatarone MA, Marks EC, Ryan ND, Meredith CN, Evans WJ: High-intensity strength training in nonagenarians. Effects on skeletal muscle. JAMA 263:3029-3034, 1990
16. Wenger NK: Postmenopausal hormone therapy. Is it useful for coronary prevention? Cardiol Clin 16:17-25, 1998
17. The Writing Group for the PEPI Trial: Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) trial. JAMA 273: 199-208, 1995
18. Sidney S, Petitti DB, Quesenberry CP Jr: Myocardial infarction and the use of estrogen and estrogen-progestin in postmenopausal women. Ann Intern Med 127:501-508, 1997
19. Hemminki E, McPherson K: Impact of postmenopausal hormone therapy on cardiovascular events and cancer: Pooled data from clinical trials. Br Med J 315:149-153, 1997
20. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E: Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. JAMA 280: 605-613, 1998
21. Daly E, Vessey MP, Hawkins MM, Carson JL, Gough P, Marsh S: Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 348:977-980, 1996
22. Jick H, Derby LE, Myers MW, Vasilakis C, Newton KM: Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet 348:981-983, 1996
23. Grodstein F, Stampfer MJ, Goldhaber SZ, Manson JE, Colditz GA, Speizer FE, Willed WC, Hennekens CH: Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet 348:983-987, 1996
24. Grady D, Hulley SB, Furberg C. Venous thromboembolic events associated with hormone replacement therapy. JAMA 278:477-478, 1997
25. Colditz GA, Hankinson SE, Hunter DJ, Willed WC, Manson JE, Stampfer MJ, Hennekens C, Rosner B, Speizer FE: The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 332:1589-1593, 1995
26. Grodstein F, Stampfer MJ, Colditz GA, Willed WC, Manson JE, Joffe M, Rosner B, Fuchs C, Hankinson SE, Hunter DJ, Hennekens CH, Speizer FE: Postmenopausal hormone therapy and mortality. N Engl J Med 336: 1769-1775, 1997
27. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: Collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 350:1047-1059, 1997
28. Walsh BW, Kuller LH, Wild RA, Paul S, Farmer M, Lawrence JB, Shah AS, Anderson PW: Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA 279:1445-1451, 1998